This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weiss, M. Articles by Ladisch, S. Search for Related Content PubMed PubMed Citation Articles by Weiss, M. Articles by Ladisch, S.

Inhibition of Melanoma Tumor Growth by a Novel Inhibitor of Glucosylceramide Synthase¹

Center for Cancer Research, Children’s Research Institute, and Departments of Pediatrics and Biochemistry/Molecular Biology, George Washington University School of Medicine, Washington, DC 20010 [M. W., S. H., S. L.], and Oxford Glycosciences, Abingdon, United Kingdom [P. S.]

Tumor ganglioside metabolism has been implicated in modulating tumorformation and progression. We found previously that transient ganglioside depletion by inhibition of glucosylceramide synthesis of MEB4 melanoma cells in vitro reduced their tumorigenic capability. Here, we have established that treatment of the host with a novel p.o. inhibitor of glucosylceramide synthesis, the imino sugar OGT2378, inhibits MEB4 melanoma tumor growth in a syngeneic, orthotopic murine model. The glucosylceramide and ganglioside content of MEB4 cells exposed to 20 µM OGT2378 in culture were reduced by 93 and >95%, respectively, without either cytotoxic or antiproliferative effects. Administered in the diet to C57BL/6 mice, 2500 mg/kg/day OGT2378 was well tolerated in vivo and biologically active, depleting host tissue (hepatic) gangliosides by 82% and tumor gangliosides by >98%. p.o. treatment with OGT2378 starting 3 days before intradermal tumor inoculation of 4 x 10⁴ MEB4 cells, and continuing for 4 weeks, resulted in a 10-fold lower mean tumor volume at the end of treatment (60 versus 538 mm³, P < 0.0001). Even when OGT2378 treatment was initiated 7 days after tumor inoculation, tumor growth was similarly impeded (61 versus 620 mm³, P < 0.0001), demonstrating an effect on an established tumor. The effectiveness of p.o. OGT2378 in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising and now feasible novel therapeutic approach to inhibit tumor progression.

This article has been cited by other articles:

				P. Mukherjee, A. C. Faber, L. M. Shelton, R. C. Baek, T. C. Chiles, and T. N. Seyfried Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a J. Lipid Res., May 1, 2008; 49(5): 929 - 938. [Abstract] [Full Text] [PDF]

				Y. Liu, J. McCarthy, and S. Ladisch Membrane Ganglioside Enrichment Lowers the Threshold for Vascular Endothelial Cell Angiogenic Signaling Cancer Res., November 1, 2006; 66(21): 10408 - 10414. [Abstract] [Full Text] [PDF]

				J. Jones, H. Otu, D. Spentzos, S. Kolia, M. Inan, W. D. Beecken, C. Fellbaum, X. Gu, M. Joseph, A. J. Pantuck, et al. Gene Signatures of Progression and Metastasis in Renal Cell Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5730 - 5739. [Abstract] [Full Text] [PDF]

				A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70 Cancer Res., June 15, 2005; 65(12): 5428 - 5438. [Abstract] [Full Text] [PDF]

				V. Gouaze, Y.-Y. Liu, C. S. Prickett, J. Y. Yu, A. E. Giuliano, and M. C. Cabot Glucosylceramide Synthase Blockade Down-Regulates P-Glycoprotein and Resensitizes Multidrug-Resistant Breast Cancer Cells to Anticancer Drugs Cancer Res., May 1, 2005; 65(9): 3861 - 3867. [Abstract] [Full Text] [PDF]